
Penile squamous cell carcinoma (PSCC) is linked to HPV infection, particularly HPV-16, influencing treatment response. HPV-positive PSCC shows enhanced sensitivity to chemoradiotherapy and immunotherapy, suggesting potential for treatment de-escalation. Biomarkers like tumor mutational burden and PD-L1 expression may guide personalized strategies. Tailored therapies integrating immunotherapy with radiotherapy could improve outcomes while minimizing toxicity, highlighting the need for comprehensive HPV status assessment in treatment planning.
Like
Save
Share